Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents
AssigneePfizer Inc.
InventorsGloria Hoi Ying LIN, Robert Adam UGER, Mark Michael WONG
Life of this patent
Estimating the term…
Abstract
Various forms of cancer and other diseases are treated using a medicinal combination of a SIRPαFc to block binding with CD47, and an anti-VEGF agent such as humanized antibody bevacizumab to control vascularization.
Claims28
A method for treating a subject presenting with CD47+ disease cells, comprising administering to the subject a treatment-effective combination comprising (1) a CD47-binding form of SIRPαFc, and (2) an anti-VEGF agent.
2-7. (canceled)
11-12. (canceled)
15-16. (canceled)
23-28. (canceled)
31-32. (canceled)
(canceled)
37-40. (canceled)
comprising unit dose formulations of a CD47-binding form of SIRPαFc, and an anti-VEGF agent.
Dependencies are inferred from the claim text.